Okava Pharmaceuticals Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 5

Employees

  • Latest Deal Type
  • Early Stage VC

  • Investors
  • 3

Okava Pharmaceuticals General Information

Description

Developer of pet medications intended to treat the needs of dogs and cats. The company focuses on treating chronic diseases in animals by repurposing validated human medicines to overcome the high developmental expenses associated with traditional drug development, enabling pharma companies to provide methods of treatment in a veterinary setting.

Contact Information

Website
www.okava.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 2047 Polk Street
  • Unit A
  • San Francisco, CA 94109
  • United States
Primary Industry
Other Pharmaceuticals and Biotechnology
Corporate Office
  • 2047 Polk Street
  • Unit A
  • San Francisco, CA 94109
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Okava Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC 01-Jan-2019 Completed Pre-Clinical Trials
To view Okava Pharmaceuticals’s complete valuation and funding history, request access »

Okava Pharmaceuticals Patents

Okava Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026143020-A1 Dosage forms comprising mycophenolic acid and methods of their use Pending 24-Dec-2024
CA-3111908-A1 Methods and compositions for delivering mycophenolic acid active agents to non-human mammals Inactive 07-Sep-2018
EP-3846798-A1 Methods and compositions for delivering mycophenolic acid active agents to non-human mammals Inactive 07-Sep-2018
WO-2020050863-A1 Methods and compositions for delivering mycophenolic acid active agents to non-human mammals Inactive 07-Sep-2018
AU-2018236225-A1 Methods and compositions for delivering mycophenolic acid active agents to non-human mammals Active 13-Mar-2017 A61K31/365
To view Okava Pharmaceuticals’s complete patent history, request access »

Okava Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Okava Pharmaceuticals Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Angel (individual) Minority
Venture Forward Capital Venture Capital Minority
Angel (individual) Minority
To view Okava Pharmaceuticals’s complete investors history, request access »

Okava Pharmaceuticals FAQs

  • When was Okava Pharmaceuticals founded?

    Okava Pharmaceuticals was founded in 2015.

  • Where is Okava Pharmaceuticals headquartered?

    Okava Pharmaceuticals is headquartered in San Francisco, CA.

  • What is the size of Okava Pharmaceuticals?

    Okava Pharmaceuticals has 5 total employees.

  • What industry is Okava Pharmaceuticals in?

    Okava Pharmaceuticals’s primary industry is Other Pharmaceuticals and Biotechnology.

  • Is Okava Pharmaceuticals a private or public company?

    Okava Pharmaceuticals is a Private company.

  • What is Okava Pharmaceuticals’s current revenue?

    The current revenue for Okava Pharmaceuticals is .

  • Who are Okava Pharmaceuticals’s investors?

    , Venture Forward Capital, and have invested in Okava Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process